group of international researchers conducted a randomised, phase 3 “open label” study in which 682 symptomatic patients were enrolled with a new diagnosis of multiple myeloma, who could not be treated with maximum therapy and stem cells transplantation because of their age (≥65 years) or because of the presence of concomitant diseases. Aim of this study was the comparison of the effectiveness of the treatment with melphalan and prednisone alone with that with the same drugs associated with bortezomib. The enrolled patients were randomised to perform nine cycles of therapy of 6 weeks each during which they assumed melphalan at the dosage of 9 mg/m2 of body area, and prednisone (60 mg/m2) in days from 1 to 4, alone or in combination with bortezomib (1.3 mg/m2) in days 1, 4, 8, 11, 22, 25, 29 and 32 during the first 4 cycles and in days 1, 8, 22 and 29 during the other 5 cycles. The major end point was represented by the time to disease progression; secondary end points included the percentage of complete response, the length of the response and total survival.

New evidence in oncologic and cardiocirculatory medicine / Andrea Conti; Beatrice Dilaghi; Pietro Modesti; Carlo Nozzoli. - In: INTERNAL AND EMERGENCY MEDICINE. - ISSN 1970-9366. - STAMPA. - 4:(2009), pp. 57-59. [10.1007/s11739-008-0214-3]

New evidence in oncologic and cardiocirculatory medicine.

CONTI, ANDREA;MODESTI, PIETRO AMEDEO;
2009

Abstract

group of international researchers conducted a randomised, phase 3 “open label” study in which 682 symptomatic patients were enrolled with a new diagnosis of multiple myeloma, who could not be treated with maximum therapy and stem cells transplantation because of their age (≥65 years) or because of the presence of concomitant diseases. Aim of this study was the comparison of the effectiveness of the treatment with melphalan and prednisone alone with that with the same drugs associated with bortezomib. The enrolled patients were randomised to perform nine cycles of therapy of 6 weeks each during which they assumed melphalan at the dosage of 9 mg/m2 of body area, and prednisone (60 mg/m2) in days from 1 to 4, alone or in combination with bortezomib (1.3 mg/m2) in days 1, 4, 8, 11, 22, 25, 29 and 32 during the first 4 cycles and in days 1, 8, 22 and 29 during the other 5 cycles. The major end point was represented by the time to disease progression; secondary end points included the percentage of complete response, the length of the response and total survival.
2009
4
57
59
Andrea Conti; Beatrice Dilaghi; Pietro Modesti; Carlo Nozzoli
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/348989
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact